MTOR and neoplasm: In vivo experimental results showed that anti‐PD‐L1 antibody combined with mTOR inhibitor could effectively reduce tumor proliferation with a significant reduction in PD‐L1 and KI67 expression compared with that in any other group, suggesting that anti‐PD‐L1 may have a synergetic effect with mTOR inhibitors, and the significant effect in reducing tumor volume may be due to PD‐L1 downregulation.